Endocrine Laboratory, McGill University Health Centre, 687 Avenue des Pins, Ouest, Montreal, Canada H3A 1A1.
Peptides. 2010 Apr;31(4):723-35. doi: 10.1016/j.peptides.2009.12.011. Epub 2009 Dec 16.
C21, the C-terminal residue of thrombospondin-4 (TSP-4), was identified as a peptide growth factor during an investigation concerning erythropoietin-dependent, erythroid stimulating factors of endothelial origin. It is active in cultures of several human hematopoietic stem cells, skin fibroblasts and kidney epithelial cells and stimulates red cell formation in anemic mice. A method of affinity chromatography in the presence of high concentrations of Triton X-100, previously developed for identifying proteins associated with the TSP-1 receptor CD47, was utilized for the detection of C21 binding molecules and their detergent-resistant, associated partners. These experiments helped to delineate two different mechanisms of C21 action, which are compatible with its cell proliferating activity. As a cell matrix peptide, C21 binds to the osteopontin receptor CD44 and could act as an osteopontin antagonist, preventing the inhibition of primitive hematopoietic stem cell proliferation. TSP-1, another matrix protein, binds to C21 and could indirectly act as an antagonist, by shunting C21-CD44 interactions. The second mechanism is a direct effect of C21 on cell proliferation. The extremely rapid internalization and nuclear localization of the peptide could be explained by CD44-mediated internalization, followed by a microtubule-mediated transport towards the nucleus, or, eventually, direct membrane insertion. These alternative hypotheses are supported by previously observed membrane insertion of similar synthetic and viral acidic amphipathic peptides, the presence of microtubule-associated protein 1B (MAP1B) and dynactin in the triton-soluble complexes associated with C21 and the presence in such complexes of dual compartment proteins for nuclei and plasma membranes, such as MAP1B, AHNAK and CD44.
C21 是血栓反应蛋白-4(TSP-4)的 C 末端残基,在研究内皮源性促红细胞生成素依赖性、红系刺激因子时被鉴定为一种肽类生长因子。它在几种人类造血干细胞、皮肤成纤维细胞和肾上皮细胞的培养中具有活性,并能刺激贫血小鼠红细胞的形成。先前为鉴定与 TSP-1 受体 CD47 相关的蛋白而开发的在高浓度 Triton X-100 存在下的亲和层析方法,被用于检测 C21 结合分子及其去污剂抗性相关伴侣。这些实验有助于描绘 C21 作用的两种不同机制,这与它的细胞增殖活性是一致的。作为细胞基质肽,C21 与骨桥蛋白受体 CD44 结合,可作为骨桥蛋白拮抗剂,防止原始造血干细胞增殖受到抑制。TSP-1 是另一种基质蛋白,与 C21 结合,可通过转移 C21-CD44 相互作用间接发挥拮抗作用。第二种机制是 C21 对细胞增殖的直接影响。该肽的极其迅速的内化和核定位可通过 CD44 介导的内化来解释,随后通过微管介导运输到核,或者最终通过直接膜插入。这些替代假说得到了先前观察到的类似合成和病毒酸性两亲肽的膜插入、与 C21 相关的 Triton 可溶性复合物中存在微管相关蛋白 1B(MAP1B)和动力蛋白以及此类复合物中存在核和质膜的双区室蛋白(如 MAP1B、AHNAK 和 CD44)的支持。